Ennaid Therapeutics Invited To Participate In The International Society for Neglected Tropical Diseases

Discovery, Development, Diagnostics (ISNTD d3) Conference In London, UK

ALPHARETTA, Georgia, May 23, 2016 /PRNewswire/ -- The President and CEO of Ennaid Therapeutics, Darnisha Harrison, will be speaking at the 2016 ISNTD d3 conference. The conference will take place on May 25^th and 26^th in London, United Kingdom and will address the drug discovery, development and diagnostics equation over two days. This is truly an honor for Ennaid Therapeutics as the company is diligently developing antiviral drugs to treat Zika virus, dengue virus and many other emerging mosquito-borne diseases.

The ISNTD is an independent not-for-profit organization providing a multidisciplinary global platform to alleviate the burden of NTDs on the world's poorest and most vulnerable, with the ultimate goal of reaching sustainable healthcare provision & poverty reduction in the developing world. The purpose of this conference (ISNTD d3) is to address the past shortfalls in R&D productivity and drive the development of future paths towards successful gains in the control, treatment or evaluation of NTDs. ISNTD d3 will bring together experts from within drug discovery and clinical trials to drive the debate and foster new partnerships & alliances leading to tangible outcomes in terms of new therapies to combat these diseases.

"We are honored to be selected to participate in this relevant conference," says Darnisha Harrison, Ennaid Therapeutics' President & CEO, "as we, too, have a goal to bring sustainable healthcare to the globally diverse regions of the world by developing therapeutics that bring hope to endemic countries being plagued by Zika, Dengue and Chikungunya viruses."

To find out more about ISNTD d3 Conference visit their website at www.isntdd3.com.

About Ennaid Therapeutics
Founded in 2012, Ennaid Therapeutics is developing antiviral drugs using flavivirus peptide inhibitors to treat Zika virus and dengue virus. Their rapid development plan has the potential to safely and quickly bring a Zika virus and dengue virus treatment to market in record time.

Darnisha Harrison, Ennaid Therapeutics CEO
Formerly a Microbiologist and Chemist, Ms. Harrison is a nationally recognized pharmaceutical entrepreneur by Newsweek magazine. With 22 years' experience in the life sciences, she is a member of the ISNTD, the World Chamber of Commerce, American Association for the Advancement of Science. She received a Bachelor of Science degree in Microbiology and a Minor in Chemistry from LSU.

For interviews, investment or more information contact:
Gigi Gilbert, Public Relations, Email: [e-mail]